Predicting 5-fluorouracil toxicity: DPD genotype and 5,6-dihydrouracil:uracil ratio

Pharmacogenomics

Volumn 15, Issue 13, 2014, Pages 1653-1666

  Sistonen, Johanna ^a   Büchel, Barbara ^a,b   Froehlich, Tanja K ^a,b   Kummer, Dominic ^a,b   Fontana, Stefano ^c   Joerger, Markus ^d   Van Kuilenburg, André B P ^e   Largiadèr, Carlo R ^a  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY OF BERN   (Switzerland)

^c Swiss Red Cross   (Switzerland)

^d CANTONAL HOSPITAL ST GALLEN   (Switzerland)

^e UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

5 fluorouracil; chemotherapy; dihydropyrimidine dehydrogenase; dihydrouracil; DPYD; genotype; pharmacogenomics; pharmacokinetics; uracil

Indexed keywords

DIHYDROURACIL; FLUOROURACIL; URACIL; ANTINEOPLASTIC ANTIMETABOLITE; DIHYDROPYRIMIDINE DEHYDROGENASE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CLINICAL ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; DIGESTIVE SYSTEM CANCER; DPD GENE; DRUG BLOOD LEVEL; FEMALE; GENE FREQUENCY; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HUMAN; LIQUID CHROMATOGRAPHY; MALE; MULTIPLE CYCLE TREATMENT; NUCLEOTIDE SEQUENCE; SKIN INFECTION; TANDEM MASS SPECTROMETRY; UNSPECIFIED SIDE EFFECT; ANALOGS AND DERIVATIVES; BLOOD; GENETICS; MIDDLE AGED; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; DIHYDROURACIL DEHYDROGENASE (NADP); FEMALE; FLUOROURACIL; GENOTYPE; HUMANS; MALE; MIDDLE AGED; URACIL;

EID: 84913593828     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.14.126     Document Type: Article

References (55)

1. Amstutz U, Farese S, Aebi S, Largiader CR. Dihydropyrimidine dehydrogenase gene variation and severe 5-fluorouracil toxicity: a haplotype assessment. Pharmacogenomics 10(6), 931-944 (2009).
2. Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors. Meta-Analysis Group in Cancer. J. Clin. Oncol. 16(11), 3537-3541 (1998).
3. Van Kuilenburg AB, Hausler P, Schalhorn A et al. Evaluation of 5-fluorouracil pharmacokinetics in cancer patients with a c.1905+1GA mutation in DPYD by means of a Bayesian limited sampling strategy. Clin. Pharmacokinet. 51(3), 163-174 (2012).
4. Boisdron-Celle M, Remaud G, Traore S et al. 5-fluorouracil-related severe toxicity: a comparison of different methods for the pretherapeutic detection of dihydropyrimidine dehydrogenase deficiency. Cancer Lett. 249(2), 271-282 (2007).
5. Longley DB, Harkin DP, Johnston PG. 5-fluorouracil: mechanisms of action and clinical strategies. Nat. Rev. Cancer 3(5), 330-338 (2003).
6. Canellakis ES. Pyrimidine metabolism. I. Enzymatic pathways of uracil and thymine degradation. J. Biol. Chem. 221(1), 315-322 (1956).
7. Rutman RJ, Cantarow A, Paschkis KE. The catabolism of uracil in vivo and in vitro. J. Biol. Chem. 210(1), 321-329 (1954).
8. Tuchman M, Ramnaraine ML, O'Dea RF. Effects of uridine and thymidine on the degradation of 5-fluorouracil, uracil, and thymine by rat liver dihydropyrimidine dehydrogenase. Cancer Res. 45(11 Pt 1), 5553-5556 (1985).
9. Muneoka K, Shirai Y, Yokoyama N, Wakai T, Hatakeyama K. 5-fluorouracil cardiotoxicity induced by alpha-fluoro-beta-alanine. Int. J. Clin. Oncol. 10(6), 441-443 (2005).
10. Yen-Revollo JL, Goldberg RM, McLeod HL. Can inhibiting dihydropyrimidine dehydrogenase limit hand-foot syndrome caused by fluoropyrimidines? Clin. Cancer Res. 14(1), 8-13 (2008).
11. Amstutz U, Froehlich TK, Largiader CR. Dihydropyrimidine dehydrogenase gene as a major predictor of severe 5-fluorouracil toxicity. Pharmacogenomics 12(9), 1321-1336 (2011).
12. Etienne MC, Lagrange JL, Dassonville O et al. Population study of dihydropyrimidine dehydrogenase in cancer patients. J. Clin. Oncol. 12(11), 2248-2253 (1994).
13. Lu Z, Zhang R, Diasio RB. Dihydropyrimidine dehydrogenase activity in human peripheral blood mononuclear cells and liver: population characteristics, newly identified deficient patients, and clinical implication in 5-fluorouracil chemotherapy. Cancer Res. 53(22), 5433-5438 (1993).
14. Van Kuilenburg AB, Meijer J, Mul AN et al. Intragenic deletions and a deep intronic mutation affecting pre-mRNA splicing in the dihydropyrimidine dehydrogenase gene as novel mechanisms causing 5-fluorouracil toxicity. Hum. Genet. 128(5), 529-538 (2010).
15. Deenen MJ, Tol J, Burylo AM et al. Relationship between single nucleotide polymorphisms and haplotypes in DPYD and toxicity and efficacy of capecitabine in advanced colorectal cancer. Clin. Cancer Res. 17(10), 3455-3468 (2011).
16. Gross E, Busse B, Riemenschneider M et al. Strong association of a common dihydropyrimidine dehydrogenase gene polymorphism with fluoropyrimidine-related toxicity in cancer patients. PLoS ONE 3(12), e4003 (2008).
17. Schwab M, Zanger UM, Marx C et al. Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: a prospective clinical trial by the German 5-FU Toxicity Study Group. J. Clin. Oncol. 26(13), 2131-2138 (2008).
18. Offer SM, Wegner NJ, Fossum C, Wang K, Diasio RB. Phenotypic profiling of DPYD variations relevant to 5-fluorouracil sensitivity using real-time cellular analysis and in vitro measurement of enzyme activity. Cancer Res. 73(6), 1958-1968 (2013).
19. Kleibl Z, Fidlerova J, Kleiblova P et al. Influence of dihydropyrimidine dehydrogenase gene (DPYD) coding sequence variants on the development of fluoropyrimidine-related toxicity in patients with high-grade toxicity and patients with excellent tolerance of fluoropyrimidine-based chemotherapy. Neoplasma 56(4), 303-316 (2009).
20. Seck K, Riemer S, Kates R et al. Analysis of the DPYD gene implicated in 5-fluorouracil catabolism in a cohort of Caucasian individuals. Clin. Cancer Res. 11(16), 5886-5892 (2005).
21. Morel A, Boisdron-Celle M, Fey L et al. Clinical relevance of different dihydropyrimidine dehydrogenase gene single nucleotide polymorphisms on 5-fluorouracil tolerance. Mol. Cancer Ther. 5(11), 2895-2904 (2006).
22. Mukherjee KL, Boohar J, Wentland D, Ansfield FJ, Heidelberger C. Studies on fluorinated pyrimidines XVI. Metabolism of 5-fluorouracil-2-C14 and 5-fluoro-2'-deoxyuridine-2-C14 in cancer patients. Cancer Res. 23(1), 49-66 (1963).
23. Van Kuilenburg AB, Van Lenthe H, Blom MJ, Mul EP, Van Gennip AH. Profound variation in dihydropyrimidine dehydrogenase activity in human blood cells: major implications for the detection of partly deficient patients. Br. J. Cancer 79(3-4), 620-626 (1999).
24. Chazal M, Etienne MC, Renee N, Bourgeon A, Richelme H, Milano G. Link between dihydropyrimidine dehydrogenase activity in peripheral blood mononuclear cells and liver. Clin. Cancer Res. 2(3), 507-510 (1996).
25. Gamelin E, Boisdron-Celle M, Larra F, Robert J. A simple chromatographic method for the analysis of pyrimidines and their dihydrogenated metabolites. J. Liq. Chromatogr. Relat. Technol. 20(19), 3155-3172 (1997).
26. Gamelin E, Boisdron-Celle M, Guerin-Meyer V et al. Correlation between uracil and dihydrouracil plasma ratio, fluorouracil (5-FU) pharmacokinetic parameters, and tolerance in patients with advanced colorectal cancer: a potential interest for predicting 5-FU toxicity and determining optimal 5-FU dosage. J. Clin. Oncol. 17(4), 1105-1110 (1999).
27. César IC, Cunha-Junior GF, Duarte Byrro RM, Vaz Coelho LG, Pianetti GA. A rapid HPLC-ESI-MS/MS method for determination of dihydrouracil/uracil ratio in plasma: evaluation of toxicity to 5-flurouracil in patients with gastrointestinal cancer. Ther. Drug Monit. 34(1), 59-66 (2012).
28. Ben Fredj R, Gross E, Ben Ahmed S, Hassine H, Saguem S. The dihydrouracil/uracil ratio in plasma, clinical and genetic analysis for screening of dihydropyrimidine dehydrogenase deficiency in colorectal cancer patients treated with 5-fluorouracil. Pathol. Biol. 57(6), 470-476 (2009).
29. Zhou ZW, Wang GQ, Wan de S et al. The dihydrouracil/uracil ratios in plasma and toxicities of 5-fluorouracil-based adjuvant chemotherapy in colorectal cancer patients. Chemotherapy 53(2), 127-131 (2007).
30. Jiang H, Jiang J, Hu P, Hu Y. Measurement of endogenous uracil and dihydrouracil in plasma and urine of normal subjects by liquid chromatography-tandem mass spectrometry. J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci. 769(1), 169-176 (2002).
31. Déporte R, Amiand M, Moreau A, Charbonnel C, Campion L. High-performance liquid chromatographic assay with UV detection for measurement of dihydrouracil/uracil ratio in plasma. J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci. 834(1-2), 170-177 (2006).
32. Garg MB, Lincz LF, Adler K, Scorgie FE, Ackland SP, Sakoff JA. Predicting 5-fluorouracil toxicity in colorectal cancer patients from peripheral blood cell telomere length: a multivariate analysis. Br. J. Cancer 107(9), 1525-1533 (2012).
33. Švobaite R, Solassol I, Pinguet F, Ivanauskas L, Bres J, Bressolle FM. HPLC with UV or mass spectrometric detection for quantifying endogenous uracil and dihydrouracil in human plasma. Clin. Chem. 54(9), 1463-1472 (2008).
34. Coudoré F, Roche D, Lefeuvre S et al. Validation of an ultra-high performance liquid chromatography tandem mass spectrometric method for quantifying uracil and 5,6-dihydrouracil in human plasma. J. Chromatogr. Sci. 50(10), 877-884 (2012).
35. Kristensen MH, Pedersen P, Mejer J. The value of dihydrouracil/uracil plasma ratios in predicting 5-fluorouracil-related toxicity in colorectal cancer patients. J. Int. Med. Res. 38(4), 1313-1323 (2010).
36. Remaud G, Boisdron-Celle M, Hameline C, Morel A, Gamelin E. An accurate dihydrouracil/uracil determination using improved high performance liquid chromatography method for preventing fluoropyrimidines-related toxicity in clinical practice. J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci. 823(2), 98-107 (2005).
37. Levi F, Okyar A, Dulong S, Innominato PF, Clairambault J. Circadian timing in cancer treatments. Annu. Rev. Pharmacol. Toxicol. 50, 377-421 (2010).
38. Jiang H, Lu J, Ji J. Circadian rhythm of dihydrouracil/uracil ratios in biological fluids: a potential biomarker for dihydropyrimidine dehydrogenase levels. Br. J. Pharmacol. 141(4), 616-623 (2004).
39. Mueller F, Büchel B, Köberle D et al. Gender-specific elimination of continuous-infusional 5-fluorouracil in patients with gastrointestinal malignancies: results from a prospective population pharmacokinetic study. Cancer Chemother. Pharmacol. 71(2), 361-370 (2013).
40. Sistonen J, Smith C, Fu YK, Largiader CR. A new DPYD genotyping assay for improving the safety of 5-fluorouracil therapy. Clin. Chim. Acta 414, 109-111 (2012).
41. Büchel B, Rhyn P, Schürch S, Bühr C, Amstutz U, Largiadèr CR. LC-MS/MS method for simultaneous analysis of uracil, 5,6-dihydrouracil, 5-fluorouracil and 5-fluoro-5,6-dihydrouracil in human plasma for therapeutic drug monitoring and toxicity prediction in cancer patients. Biomed. Chromatogr. 27(1), 7-16 (2013).
42. Excoffier L, Lischer HE. Arlequin suite ver 3.5: a new series of programs to perform population genetics analyses under Linux and Windows. Mol. Ecol. Resour. 10(3), 564-567 (2010).
43. Rosenberg MS, Anderson CD. PASSaGE: Pattern Analysis, Spatial Statistics and Geographic Exegesis. Version 2. Methods Ecol. Evol. 2(3), 229-232 (2011).
44. Legendre P, Fortin MJ. Comparison of the Mantel test and alternative approaches for detecting complex multivariate relationships in the spatial analysis of genetic data. Mol. Ecol. Resour. 10(5), 831-844 (2010).
45. Fieller EC. The biological standardization of insulin. Suppl. J. R. Stat. Soc. 7(1), 1-64 (1940).
46. Van Staveren MC, Theeuwes-Oonk B, Guchelaar HJ, Van Kuilenburg AB, Maring JG. Pharmacokinetics of orally administered uracil in healthy volunteers and in DPD-deficient patients, a possible tool for screening of DPD deficiency. Cancer Chemother. Pharmacol. 68(6), 1611-1617 (2011).
47. Offer SM, Lee AM, Mattison LK, Fossum C, Wegner NJ, Diasio RB. A DPYD variant (Y186C) in individuals of African ancestry is associated with reduced DPD enzyme activity. Clin. Pharmacol. Ther. 94(1), 158-166 (2013).
48. Gross E, Ullrich T, Seck K et al. Detailed analysis of five mutations in dihydropyrimidine dehydrogenase detected in cancer patients with 5-fluorouracil-related side effects. Hum. Mutat. 22(6), 498 (2003).
49. Loganayagam A, Arenas Hernandez M, Corrigan A et al. Pharmacogenetic variants in the DPYD, TYMS, CDA and MTHFR genes are clinically significant predictors of fluoropyrimidine toxicity. Br. J. Cancer 108(12), 2505-2515 (2013).
50. Wettergren Y, Carlsson G, Odin E, Gustavsson B. Pretherapeutic uracil and dihydrouracil levels of colorectal cancer patients are associated with sex and toxic side effects during adjuvant 5-fluorouracil-based chemotherapy. Cancer 118(11), 2935-2943 (2012).
51. Milano G, Chamorey AL. Clinical pharmacokinetics of 5-fluorouracil with consideration of chronopharmacokinetics. Chronobiol. Int. 19(1), 177-189 (2002).
52. Abolmaali K, Balakrishnan A, Stearns AT et al. Circadian variation in intestinal dihydropyrimidine dehydrogenase (DPD) expression: a potential mechanism for benefits of 5FU chrono-chemotherapy. Surgery 146(2), 269-273 (2009).
53. Stein BN, Petrelli NJ, Douglass HO, Driscoll DL, Arcangeli G, Meropol NJ. Age and sex are independent predictors of 5-fluorouracil toxicity. Analysis of a large scale Phase III trial. Cancer 75(1), 11-17 (1995).
54. Nakayama Y, Matsumoto K, Inoue Y et al. Correlation between the urinary dihydrouracil-uracil ratio and the 5-FU plasma concentration in patients treated with oral 5-FU analogs. Anticancer Res. 26(5B), 3983-3988 (2006).
55. McLeod HL, Sludden J, Hardy SC, Lock RE, Hawksworth GM, Cassidy J. Autoregulation of 5-fluorouracil metabolism. Eur. J. Cancer 34(10), 1623-1627 (1998).